Myeloid/Lymphoid Neoplasms with ETV6::PDGFRB Fusion Gene: A Rare Case of Poor Response to Imatinib and Possible Transformation Mechanisms from Myeloid Neoplasms of Bone Marrow to T-Cell Lymphoblastic Lymphoma Invasion in Lymph Nodes

References

• Pozdnyakova O, Orazi A, Kelemen K, et al. Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2. Am J Clin Pathol. 2021;155(2):160–178. doi:10.1093/ajcp/aqaa208
   PubMed Web of Science ®Google Scholar
• Appiah-Kubi K, Lan T, Wang Y, et al. Platelet-derived growth factor receptors (PDGFRs) fusion genes involvement in hematological malignancies. Crit Rev Oncol Hematol. 2017;109:20–34. doi:10.1016/j.critrevonc.2016.11.008
   PubMed Web of Science ®Google Scholar
• Havelange V, Demoulin JB. Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia. J Blood Med. 2013;4:111–121. doi:10.2147/JBM.S33142
   PubMedGoogle Scholar
• Di Giacomo D, Quintini M, Pierini V, et al. Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement. Ann Hematol. 2022;101(2):297–307. doi:10.1007/s00277-021-04712-8
   PubMed Web of Science ®Google Scholar
• Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77(2):307–316. doi:10.1016/0092-8674(94)90322-0
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–1228. doi:10.1182/blood.2022015850
   PubMed Web of Science ®Google Scholar
• Jawhar M, Naumann N, Schwaab J, et al. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol. 2017;96(9):1463–1470. doi:10.1007/s00277-017-3067-x
   PubMed Web of Science ®Google Scholar
• Ondrejka SL, Jegalian AG, Kim AS, et al. PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin. Haematologica. 2014;99(9):e148–e151. doi:10.3324/haematol.2014.105452
   PubMed Web of Science ®Google Scholar
• De Braekeleer E, Douet-Guilbert N, Morel F, et al. ETV6 fusion genes in hematological malignancies: a review. Leuk Res. 2012;36(8):945–961. doi:10.1016/j.leukres.2012.04.010
   PubMed Web of Science ®Google Scholar
• Telford N, Alexander S, McGinn OJ, et al. Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusion. Blood Cancer J. 2016;6(4):e412. doi:10.1038/bcj.2016.11
   PubMedGoogle Scholar
• McCormack MP. T/myeloid MPAL: origin and pathogenesis. Blood. 2022;139(3):313–315. doi:10.1182/blood.2021014129
   PubMed Web of Science ®Google Scholar
• Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017;129(6):704–714. doi:10.1182/blood-2016-10-695973
   PubMed Web of Science ®Google Scholar
• Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014;123(23):3574–3577. doi:10.1182/blood-2014-02-555607
   PubMed Web of Science ®Google Scholar
• Metzgeroth G, Schwaab J, Gosenca D, et al. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia. 2013;27(11):2254–2256. doi:10.1038/leu.2013.129
   PubMed Web of Science ®Google Scholar
• Demoulin JB, Montano-Almendras CP. Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. Am J Blood Res. 2012;2(1):44–56.
   PubMedGoogle Scholar
• Montano-Almendras CP, Essaghir A, Schoemans H, et al. ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-kappaB. Haematologica. 2012;97(7):1064–1072. doi:10.3324/haematol.2011.047530
   PubMed Web of Science ®Google Scholar
• Bellavia D, Campese AF, Checquolo S, et al. Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci U S A. 2002;99(6):3788–3793. doi:10.1073/pnas.062050599
   PubMed Web of Science ®Google Scholar
• Fernandez-Martinez JL, deAndres-Galiana EJ, Sonis ST. Genomic data integration in chronic lymphocytic leukemia. J Gene Med. 2017;19(1–2):e2936.
   Web of Science ®Google Scholar
• Spinella JF, Cassart P, Richer C, et al. Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations. Oncotarget. 2016;7(40):65485–65503. doi:10.18632/oncotarget.11796
   PubMedGoogle Scholar
• Ritchie KA, Aprikyan AA, Bowen-Pope DF, et al. The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice. Leukemia. 1999;13(11):1790–1803. doi:10.1038/sj.leu.2401494
   PubMed Web of Science ®Google Scholar
• Cain JA, Xiang Z, O’Neal J, et al. Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood. 2007;109(9):3906–3914. doi:10.1182/blood-2006-07-036335
   PubMed Web of Science ®Google Scholar
• Schmidt CA, Przybylski GK. What can we learn from leukemia as for the process of lineage commitment in hematopoiesis? Int Rev Immunol. 2001;20(1):107–115. doi:10.3109/08830180109056725
   PubMedGoogle Scholar
• Jamil SF, Sharma U, Singh C, et al. Lineage switch of acute myeloid leukemia to T-Cell acute lymphoblastic leukemia - A unique case report. Indian J Pathol Microbiol. 2023;66(1):191–195. doi:10.4103/ijpm.ijpm_441_21
   PubMed Web of Science ®Google Scholar
• Banerji L, Sattler M. Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias. Expert Opin Ther Targets. 2004;8(3):221–239. doi:10.1517/14728222.8.3.221
   PubMed Web of Science ®Google Scholar
• Wang X, Huang R, Zhang X, Zhang X. Current status and prospects of hematopoietic stem cell transplantation in China. Chin Med J. 2022;135(12):1394–1403. doi:10.1097/CM9.0000000000002235
   PubMed Web of Science ®Google Scholar